| MNPs | Marine natural products |
| FDA | United States Food and Drug Administration |
| EMA | European Medicines Agency |
| OIDD | The Lilly Open Innovation Drug Discovery Program |
| TZD | Thiazolidinon-2-yl |
| THP | Tetrahydropyran |
| JAK | Janus kinase |
| STATs | Signal transducers and activators of transcription |
| VEGF | Vascular endothelial growth factor |
| FLT3 | Fms-like tyrosine kinase 3 |
| RTK | Receptor tyrosine kinase |
| RAS | Rat sarcoma viral oncogene homolog |
| PI3K | Phosphatidylinositol-4,5-biphopshate 3-kinase |
| Ephrin | Eph receptor interacting protein |
| ABL1 | Abelson murine leukemia viral oncogene homolog 1 |
| CML | Chronic myeloid leukemia |
| bFGF | Basic fibroblast growth factor |
| TIE | Tyrosine kinases with immunoglobulin-like and EGF-like domains |
| VEGFRs | Vascular endothelial growth factor receptors |
| Grb2 | Growth factor receptor-bound protein 2 |
| EGF | Epidermal growth factor |
| Ang | Angiopoietin |
| GSK3-β | Glycogen synthase kinase-3-beta |
| PLK | Polo-like kinase |
| SAR | Structure-activity relationship |
| ECFCs | Endothelial colony-forming cells |
| ADSCs | Human adipose-derived stem cells |
| cLogP | Calculated logarithm of partition coefficient |
| HBD | Hydrogen bond donor |
| HBA | Hydrogen bond acceptor |